Rationale, Opportunities, and Reality of Biosimilar Medications

Biologic therapies for cancer and other disorders contribute to improved outcomes for many patients but also account for a large proportion of health care expenditures. Opportunities for cost containment may emerge as the patents on originator products expire and highly similar agents known as…

Read the full post on The New England Journal of Medicine: Search Results in Health Policy and Reform